(S)-(+)-Ketamine hydrochloride

Pricing Availability   Qty
说明: NMDA receptor antagonist; enantiomer of ketamine hydrochloride (Cat. No. 3131); neuroprotective
化学名: (S)-(+)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride
纯度: ≥99% (HPLC)
说明书
引用文献
评论
文献 (2)

生物活性 for (S)-(+)-Ketamine hydrochloride

(S)-(+)-Ketamine hydrochloride is a NMDA receptor antagonist. Displays neuroprotective efficacy in vitro.

Racemate also available.

技术数据 for (S)-(+)-Ketamine hydrochloride

分子量 274.19
公式 C13H16ClNO.HCl
储存 Store at RT
纯度 ≥99% (HPLC)
CAS Number 33643-47-9
PubChem ID 44632368
InChI Key VCMGMSHEPQENPE-ZOWNYOTGSA-N
Smiles O=C1[C@](C2=CC=CC=C2Cl)(NC)CCCC1.Cl

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for (S)-(+)-Ketamine hydrochloride

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
water 27.42 100
DMSO 27.42 100

制备储备液 for (S)-(+)-Ketamine hydrochloride

以下数据基于产品分子量 274.19。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 3.65 mL 18.24 mL 36.47 mL
5 mM 0.73 mL 3.65 mL 7.29 mL
10 mM 0.36 mL 1.82 mL 3.65 mL
50 mM 0.07 mL 0.36 mL 0.73 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for (S)-(+)-Ketamine hydrochloride

分析证书/产品说明书
选择另一批次:

参考文献 for (S)-(+)-Ketamine hydrochloride

参考文献是支持产品生物活性的出版物。

Ryder et al (1978) Comparative pharmacology of the optical isomers of KA in mice. Eur.J.Pharmacol. 49 15 PMID: 658124

Proescholdt et al (2001) Neuroprotection of S(+) KA isomer in global forebrain ischemia. Brain Res. 904 245 PMID: 11406122

Benrath et al (2005) Low dose of S(+)-KA prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo. Br.J.Anaesth. 95 518 PMID: 16113037


If you know of a relevant reference for (S)-(+)-Ketamine hydrochloride, please let us know.

关键词: (S)-(+)-Ketamine hydrochloride, (S)-(+)-Ketamine hydrochloride supplier, nmda, nmdar, antagonists, NMDA, Receptors, Ketamine, and, Metabolites, 4379, Tocris Bioscience

篇 (S)-(+)-Ketamine hydrochloride 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 (S)-(+)-Ketamine hydrochloride 的引用文献。 您是否知道使用了 Tocris (S)-(+)-Ketamine hydrochloride 的优秀论文? 请告知我们.

(S)-(+)-Ketamine hydrochloride 的评论

目前没有该产品的评论。 Be the first to review (S)-(+)-Ketamine hydrochloride and earn rewards!

Have you used (S)-(+)-Ketamine hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.